Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of intraperitoneally (IP) injected phencyclidine (phencyclohexyl piperidine;
PCP
) on the metabolism of dopamine (DA) and cholecystokinin-like immunoreactivity (CCK-LI) in the rat brain were investigated in connection with
PCP
-induced behavioral changes. The predominant behavior change elicited by 2.5 mg/kg
PCP
was locomotion, while with higher doses (5 and 10 mg/kg) sniffing, swaying and falling were observed in addition to the enhanced locomotor activity. Backpedaling and rotation were observed in 10 mg/kg
PCP
-treated rats. IP injection of
PCP
caused a dose-related increase in the levels of DA and 3,4-dihydroxy-
phenylacetic acid
(DOPAC) in the medial frontal cortex (MFC) and anterior cingulate cortex (ant.CC) without any changes in the nucleus accumbens (NAc) or striatum. CCK-LI in the MFC, ant.CC and NAc was decreased in a dose-dependent manner following IP injection of
PCP
. These findings support the evidence that
PCP
selectively activates the mesocortical DA systems. Furthermore, our results indicate a functional relationship between the mesocortical DA neurons and intrinsic CCK containing cortical neurons, and the change in the activity of the intrinsic CCK-containing cortical neurons in these two areas, perhaps due to an alteration in DA transmission, might be involved in behavioral changes after
PCP
injection.
...
PMID:The effects of intraperitoneally administered phencyclidine on the central nervous system: behavioral and neurochemical studies. 194 26
We have examined the effects of schizophrenomimetic drugs including phencyclidine (
PCP
) and methamphetamine (MAP) on cortical and striatal dopamine (DA) metabolism using an in vivo dialysis technique in the rat. An acute systemic injection of
PCP
(2.5-10 mg/kg, intraperitoneally (i.p.)) dramatically increased concentrations of DA, 3,4-dihydroxy-
phenylacetic acid
, and homovanillic acid in the dialysates from the medial frontal cortex in a dose-dependent fashion. However,
PCP
(2.5-10 mg/kg, i.p.) caused a much lower augmentation of extracellular DA release, with a significant decrease in dialysate DOPAC levels in the striatum. Moreover, continuous infusion of tetrodotoxin (TTX, 10(-5) M) into the prefrontal or striatal region through the microdialysis tube completely blocked the ability of
PCP
(10 mg/kg, i.p.) to alter the extracellular release of DA and its metabolites in the respective areas. In contrast, MAP (4.8 mg/kg, i.p.) elicited a marked and tetrodotoxin-resistant increase in DA levels with a significant loss of DOPAC contents in the extracellular space of both the frontal cortex and the striatum. The present results clearly demonstrate the differential effects of
PCP
on cortical and striatal DA transmission, suggesting that
PCP
may facilitate DA release in the medial frontal cortex by increasing impulse flow in the DA neurons projecting to the cortical area, whereas
PCP
-induced elevation of extracellular DA in the striatum may be caused mainly by reuptake inhibition of DA liberated by basal activity of the striatal DA neurons. The regional variation in
PCP
-induced DA release would be due to the combination of NMDA (N-methyl-D-aspartate) receptor blocking and DA reuptake inhibition by the drug. The uniform and TTX-resistant nature of MAP-induced changes in brain DA metabolism may result from the direct actions of MAP at DA nerve terminals.
...
PMID:Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. 886 25
